Current evidence indicates that RUNX1 and CBFβ are among the 30 most frequently mutated genes in breast cancer (Ariffin, 2022; Griffith et al., 2018; Koboldt et al., 2012), with a prevalence of approximately 4%–5% in breast cancer cases. This evidence concerns the gene CBFB and breast carcinoma.